Lates News

Every net AI news, Huaxia Securities issued a research report on September 22 giving a buy rating to EDI Pharmaceuticals (688488.SH). The rating reasons mainly include: 1) revenue growth rate decreases expense ratio, stable investment in research and development; 2) ACC017 research selected by authoritative conference, potential for first-line starting treatment; 3) self-developed long-acting preventive formulation is about to apply for IND, layout of over half a year dosing cycle. (Daily Economic News)